Page 15 - Locally Advanced News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Transcenta to Present Trial in Progress at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

United statesLos angelesCaroline germaWeijian guoTranscenta holdingProduct development centerClinical development centers in princetonTranslational research centerGroup headquartersPrnewswire transcenta holding limitedFudan university shanghai cancer centerGlobal medicine developmentTranscenta immune tolerance breaking technologyHolding limitedHigh affinity humanized anti claudinLate line treatment

New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA

/PRNewswire/ Biofidelity, a revolutionary genomic technology company, has developed a low-cost, simple and rapid assay for single-molecule detection of.

United kingdomLiz dowlingBarnaby balmforthWendy levinPrnewswire biofidelityClinical cancer researchBiofidelity co founderSimplified molecular profilingLocally advancedMetastatic non small cell lung cancerTargetable kinase fusionsMitogenic driver alteration detectedLow tumor mutationClinical cancer

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomDan budwickVince millerCstone pharmaceuticalsDrug administrationNational medical products administrationEqrx incAmerican cancer societyInternational associationLung cancerLocally advancedMultimodality treatmentNon small cell lung cancerResponse evaluation criteriaSolid tumors

EQRx, Inc : EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free

United statesUnited kingdomDan budwickVince millerCstone pharmaceuticalsDrug administrationNational medical products administrationAmerican cancer societyInternational associationLung cancerLocally advancedMultimodality treatmentNon small cell lung cancerResponse evaluation criteriaSolid tumorsBreakthrough therapy

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer - Press Release

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstra

United statesUnited kingdomDan budwickVince millerCstone pharmaceuticalsDrug administrationNational medical products administrationEqrx incAmerican cancer societyInternational associationLung cancerLocally advancedMultimodality treatmentNon small cell lung cancerResponse evaluation criteriaSolid tumors